202 related articles for article (PubMed ID: 30883864)
1. Pharmacokinetics and subjective effects of a novel oral LSD formulation in healthy subjects.
Holze F; Duthaler U; Vizeli P; Müller F; Borgwardt S; Liechti ME
Br J Clin Pharmacol; 2019 Jul; 85(7):1474-1483. PubMed ID: 30883864
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide in Healthy Subjects.
Dolder PC; Schmid Y; Steuer AE; Kraemer T; Rentsch KM; Hammann F; Liechti ME
Clin Pharmacokinet; 2017 Oct; 56(10):1219-1230. PubMed ID: 28197931
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and Concentration-Effect Relationship of Oral LSD in Humans.
Dolder PC; Schmid Y; Haschke M; Rentsch KM; Liechti ME
Int J Neuropsychopharmacol; 2015 Jun; 19(1):. PubMed ID: 26108222
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide Microdoses in Healthy Participants.
Holze F; Liechti ME; Hutten NRPW; Mason NL; Dolder PC; Theunissen EL; Duthaler U; Feilding A; Ramaekers JG; Kuypers KPC
Clin Pharmacol Ther; 2021 Mar; 109(3):658-666. PubMed ID: 32975835
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics, pharmacodynamics and urinary recovery of oral lysergic acid diethylamide administration in healthy participants.
Holze F; Erne L; Duthaler U; Liechti ME
Br J Clin Pharmacol; 2024 Jan; 90(1):200-208. PubMed ID: 37596682
[TBL] [Abstract][Full Text] [Related]
6. Safety, tolerability, pharmacokinetics, and pharmacodynamics of low dose lysergic acid diethylamide (LSD) in healthy older volunteers.
Family N; Maillet EL; Williams LTJ; Krediet E; Carhart-Harris RL; Williams TM; Nichols CD; Goble DJ; Raz S
Psychopharmacology (Berl); 2020 Mar; 237(3):841-853. PubMed ID: 31853557
[TBL] [Abstract][Full Text] [Related]
7. Genetic influence of CYP2D6 on pharmacokinetics and acute subjective effects of LSD in a pooled analysis.
Vizeli P; Straumann I; Holze F; Schmid Y; Dolder PC; Liechti ME
Sci Rep; 2021 May; 11(1):10851. PubMed ID: 34035391
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and subjective effects of 1P-LSD in humans after oral and intravenous administration.
Grumann C; Henkel K; Brandt SD; Stratford A; Passie T; Auwärter V
Drug Test Anal; 2020 Aug; 12(8):1144-1153. PubMed ID: 32415750
[TBL] [Abstract][Full Text] [Related]
9. Acute Effects of Lysergic Acid Diethylamide on Circulating Steroid Levels in Healthy Subjects.
Strajhar P; Schmid Y; Liakoni E; Dolder PC; Rentsch KM; Kratschmar DV; Odermatt A; Liechti ME
J Neuroendocrinol; 2016 Mar; 28(3):12374. PubMed ID: 26849997
[TBL] [Abstract][Full Text] [Related]
10. Acute effects of MDMA and LSD co-administration in a double-blind placebo-controlled study in healthy participants.
Straumann I; Ley L; Holze F; Becker AM; Klaiber A; Wey K; Duthaler U; Varghese N; Eckert A; Liechti ME
Neuropsychopharmacology; 2023 Dec; 48(13):1840-1848. PubMed ID: 37258715
[TBL] [Abstract][Full Text] [Related]
11. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
Chen C; Bujanover S; Kareht S; Rapoport AM
Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
[TBL] [Abstract][Full Text] [Related]
12. Acute Effects of Lysergic Acid Diethylamide in Healthy Subjects.
Schmid Y; Enzler F; Gasser P; Grouzmann E; Preller KH; Vollenweider FX; Brenneisen R; Müller F; Borgwardt S; Liechti ME
Biol Psychiatry; 2015 Oct; 78(8):544-53. PubMed ID: 25575620
[TBL] [Abstract][Full Text] [Related]
13. Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects.
Holze F; Vizeli P; Ley L; Müller F; Dolder P; Stocker M; Duthaler U; Varghese N; Eckert A; Borgwardt S; Liechti ME
Neuropsychopharmacology; 2021 Feb; 46(3):537-544. PubMed ID: 33059356
[TBL] [Abstract][Full Text] [Related]
14. Development and validation of an LC-MS/MS method to quantify lysergic acid diethylamide (LSD), iso-LSD, 2-oxo-3-hydroxy-LSD, and nor-LSD and identify novel metabolites in plasma samples in a controlled clinical trial.
Dolder PC; Liechti ME; Rentsch KM
J Clin Lab Anal; 2018 Feb; 32(2):. PubMed ID: 28548305
[TBL] [Abstract][Full Text] [Related]
15. Ketanserin Reverses the Acute Response to LSD in a Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Healthy Participants.
Becker AM; Klaiber A; Holze F; Istampoulouoglou I; Duthaler U; Varghese N; Eckert A; Liechti ME
Int J Neuropsychopharmacol; 2023 Feb; 26(2):97-106. PubMed ID: 36342343
[TBL] [Abstract][Full Text] [Related]
16. Comparative acute effects of mescaline, lysergic acid diethylamide, and psilocybin in a randomized, double-blind, placebo-controlled cross-over study in healthy participants.
Ley L; Holze F; Arikci D; Becker AM; Straumann I; Klaiber A; Coviello F; Dierbach S; Thomann J; Duthaler U; Luethi D; Varghese N; Eckert A; Liechti ME
Neuropsychopharmacology; 2023 Oct; 48(11):1659-1667. PubMed ID: 37231080
[TBL] [Abstract][Full Text] [Related]
17. Acute Subjective and Behavioral Effects of Microdoses of Lysergic Acid Diethylamide in Healthy Human Volunteers.
Bershad AK; Schepers ST; Bremmer MP; Lee R; de Wit H
Biol Psychiatry; 2019 Nov; 86(10):792-800. PubMed ID: 31331617
[TBL] [Abstract][Full Text] [Related]
18. Safety pharmacology of acute LSD administration in healthy subjects.
Holze F; Caluori TV; Vizeli P; Liechti ME
Psychopharmacology (Berl); 2022 Jun; 239(6):1893-1905. PubMed ID: 34515824
[TBL] [Abstract][Full Text] [Related]
19. The effects of microdose LSD on time perception: a randomised, double-blind, placebo-controlled trial.
Yanakieva S; Polychroni N; Family N; Williams LTJ; Luke DP; Terhune DB
Psychopharmacology (Berl); 2019 Apr; 236(4):1159-1170. PubMed ID: 30478716
[TBL] [Abstract][Full Text] [Related]
20. Distinct acute effects of LSD, MDMA, and D-amphetamine in healthy subjects.
Holze F; Vizeli P; Müller F; Ley L; Duerig R; Varghese N; Eckert A; Borgwardt S; Liechti ME
Neuropsychopharmacology; 2020 Feb; 45(3):462-471. PubMed ID: 31733631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
